GlassScriptPhysician profile
Christian Francis
NPI 1780247262
$9,112.37
in general payments reported to CMS, 2019-2025
39 companies · $4,291 in 2025
The $4,291 reported for 2025 was more than what 99% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $586 · 2023: $1,935 · 2024: $2,301 · 2025: $4,291.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,182 · Honoraria: $2,275 · Education: $68.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,182.00 |
| Honoraria | $2,275.00 |
| Education | $68.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $2,394.89 | 2025 | Sunosi, Auvelity, Symbravo |
| Novo Nordisk INC | $905.37 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $772.52 | 2022-2025 | |
| Glaxosmithkline, LLC. | $690.22 | 2022-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Astrazeneca Pharmaceuticals LP | $576.91 | 2023-2025 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $522.43 | 2023-2025 | |
| Lilly USA, LLC | $506.51 | 2022-2025 | Jardiance, Zepbound, Mounjaro |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $299.96 | 2022-2025 | Xifaxan |
| Astellas Pharma US INC | $209.51 | 2023-2024 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $189.79 | 2022-2025 | |
| Xeris Pharmaceuticals, INC. | $184.68 | 2023-2025 | Gvoke Hypopen |
| Dexcom, INC. | $171.85 | 2022-2025 | Dexcom G6 Transmitter |
| Amgen INC. | $169.26 | 2023-2024 | Repatha, Otezla, Prolia |
| Shield Therapeutics INC | $146.36 | 2023-2025 | Accrufer |
| Janssen Pharmaceuticals, INC | $141.84 | 2023-2025 | Spravato, Xarelto |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $138.94 | 2023-2024 | Cologuard Collection Kit |
| E.R. Squibb & Sons, L.L.C. | $135.97 | 2022-2025 | Eliquis, Camzyos |
| Novartis Pharmaceuticals Corporation | $122.30 | 2022-2024 | |
| Silk Road Medical, INC. | $119.31 | 2024 | Enroute Transcarotid Neuroprotection System, Enroute Transcarotid Stent, Enroute Enflate Transcarotid Rx Balloon Dilatation Catheter |
| Phathom Pharmaceuticals, INC. | $97.66 | 2024-2025 | Voquezna |
| Boehringer Ingelheim Pharmaceuticals, INC. | $86.03 | 2022-2024 | Jardiance, Ofev |
| Idorsia Pharmaceuticals US INC | $72.05 | 2023-2024 | Quviviq |
| Merck Sharp & Dohme LLC | $56.73 | 2023-2024 | Verquvo, Belsomra, Gardasil |
| Sanofi-Aventis U.S. LLC | $53.28 | 2022-2023 | |
| Alnylam Pharmaceuticals INC. | $41.55 | 2025 | Givlaari |
| Boston Scientific Corporation | $39.18 | 2023 | Superion Indirect Decompression System |
| Lundbeck LLC | $33.98 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $29.04 | 2022 | |
| Sumitomo Pharma America, INC. | $27.35 | 2023-2025 | Gemtesa |
| American Orthodontics Corporation | $25.09 | 2022 | |
| Daiichi Sankyo INC. | $23.16 | 2023 | Injectafer |
| Biohaven Pharmaceutical Holding Company LTD. | $20.80 | 2022 | |
| Bausch Health US, LLC | $19.88 | 2022 | |
| Kyowa Kirin, INC. | $17.10 | 2024 | Crysvita |
| Seqirus USA INC | $16.99 | 2025 | Fluad, Flucelvax |
| Heartflow, INC. | $14.77 | 2025 | |
| Dynavax Technologies Corporation | $14.61 | 2024 | Heplisav-B |
| Horizon Therapeutics Plc | $12.72 | 2022 | |
| Ortho Organizers, INC. | $11.78 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christian Francis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.